Chat with us, powered by LiveChat
  • Get inspired by peer-reviewed publications of our scientists, partners, and customers around the globe.

  • Giving you some food for thought. Read our blogs to learn more about 3D tissue culture, research backgrounds, developments, and its future outlook.
  • Get inspired by research done by our scientists, partners, and customers around the globe.

  • Learn about our mission, vision, the history of the company, and find out what we mean with MIMETAS-do.
open menu icon close menu icon

Pancreatic Ductal Adenocarcinoma (PDAC) Modeling and Drug Screening with Organ-on-a-Chip

On-demand Webinar

Pancreatic Ductal Adenocarcinoma (PDAC) is the most common pancreatic cancer and is expected to become one of the deadliest cancer types by 2030, with mortality rates up to 93%. However, this disease remains difficult to predict, detect, diagnose, and treat.

A major contributor to this problem is the complex tumor microenvironment of PDAC, whereby recapitulating the intricacy of the disease in one single in vitro microenvironment is challenging. As such, most in vitro PDAC models have limited translational relevance, as these fail to imitate relevant aspects of the tumor microenvironment. Alternatively, in vivo methods are time- and cost-intensive, pose ethical problems, and in some cases lack cell-interaction with other cell types.

Altogether, there is an urgent need for novel and innovative PDAC modeling systems. A promising platform to effectively model this disease is Organ-on-a-Chip technologies such as the OrganoPlate®. In this webinar, we will discuss current methods used to study PDAC and highlight the advantages of Organ-on-a-Chip technology for modelling bio- and physicochemical features of the disease.

In this webinar, you will learn about:

  • The complex microenvironment of PDAC and the challenges of modeling the disease;
  • Advantages and disadvantages of modeling PDAC with conventional in vitro and in vivo methods;
  • How Organ-on-a-chip technology can be used as translational models that enable phenotypic drug screenings, whilst also supporting the development of novel personalized models used to identify treatment responsive patient subset.

Register Here


Marlene Geyer, Ph.D. at MIMETAS

Related publications




‘May we use cookies?
Hi there! Thanks for visiting our website. We use cookies to keep track of our website statistics to optimize the user experience. We also use cookies for marketing purposes. You can set your preferences by selecting the options below. Terms of Use & Privacy Policy

Accept all
Accept selected
Decline all